New engineered immune cells target tough leukemia
NCT ID NCT06871410
Summary
This early-stage study is testing the safety and best dose of a new cell therapy called CD83 CAR T cells for adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. Doctors take a patient's own immune cells, modify them in a lab to target a protein found on the cancer cells, and then infuse them back into the patient. The main goal is to see if this approach is safe and tolerable while also looking for early signs that it might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.